SEngine Precision Medicine

Seattle

SEngine Precision Medicine develops tests that culture patient tumor cells to assess their responses to various cancer therapies, providing personalized treatment options for cancer patients.

Facts

HQ
Seattle
Sectors
Healthcare, Biotech, Precision Medicine, Cancer Diagnostics
Stage
Series A
Members see funding amounts.
.

Is this your organization? Claim it

Fred Hutch spinout SEngine Precision Medicine raises $5.1M Series A to commercialize PARIS tumor‑testing platform

SEngine Precision Medicine raised $5.1 million to commercialize its PARIS platform, which grows patients’ tumor cells in the lab to test safety and effectiveness of over 200 drugs or drug combinations and help match cancer patients to therapies. The company also gathers data for drug discovery, has a joint venture with Atomwise, and completed a Series A led by the Bangarang Group.

SEngine Precision Medicine raises $3M (round now $8.2M), adds Nobel laureate Lee Hartwell and investor Elliott Burkland to board

SEngine Precision Medicine raised $3 million, bringing its current round to $8.2 million, and appointed former Fred Hutch president and Nobel laureate Dr. Lee Hartwell to its board; new investor Elliott Burkland of Bangarang Group will also join the board. The company uses its PARIS test to grow patients’ tumor cells as organoids and analyze drug combinations to personalize cancer treatment.